Two Sigma Advisers LP Reduces Stock Holdings in Masimo Co. (NASDAQ:MASI)

Two Sigma Advisers LP reduced its position in shares of Masimo Co. (NASDAQ:MASI - Free Report) by 97.9% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 4,500 shares of the medical equipment provider's stock after selling 214,100 shares during the quarter. Two Sigma Advisers LP's holdings in Masimo were worth $744,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors also recently bought and sold shares of MASI. Jones Financial Companies Lllp bought a new position in shares of Masimo during the 4th quarter worth $27,000. Blue Trust Inc. lifted its stake in Masimo by 56.3% in the fourth quarter. Blue Trust Inc. now owns 197 shares of the medical equipment provider's stock worth $33,000 after acquiring an additional 71 shares during the period. EverSource Wealth Advisors LLC grew its holdings in Masimo by 40.0% during the 4th quarter. EverSource Wealth Advisors LLC now owns 224 shares of the medical equipment provider's stock worth $37,000 after acquiring an additional 64 shares in the last quarter. Smartleaf Asset Management LLC grew its holdings in Masimo by 31.6% during the 4th quarter. Smartleaf Asset Management LLC now owns 250 shares of the medical equipment provider's stock worth $42,000 after acquiring an additional 60 shares in the last quarter. Finally, SBI Securities Co. Ltd. purchased a new position in Masimo during the 4th quarter valued at about $46,000. 85.96% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on the stock. Wells Fargo & Company lowered their price target on shares of Masimo from $205.00 to $190.00 and set an "overweight" rating for the company in a research report on Wednesday, May 7th. Needham & Company LLC reissued a "hold" rating on shares of Masimo in a research note on Thursday, April 10th. Raymond James dropped their target price on Masimo from $204.00 to $185.00 and set an "outperform" rating on the stock in a research report on Wednesday, May 7th. Piper Sandler reiterated an "overweight" rating and issued a $200.00 price target (down from $215.00) on shares of Masimo in a report on Wednesday, May 7th. Finally, Wall Street Zen cut Masimo from a "buy" rating to a "hold" rating in a research note on Friday, May 30th. Two analysts have rated the stock with a hold rating and five have issued a buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $191.60.

Masimo Stock Up 4.4%

NASDAQ:MASI traded up $7.25 during mid-day trading on Friday, hitting $171.97. 910,113 shares of the company's stock traded hands, compared to its average volume of 644,717. The company has a fifty day moving average of $157.05 and a 200 day moving average of $167.29. The company has a debt-to-equity ratio of 0.50, a quick ratio of 1.11 and a current ratio of 2.01. Masimo Co. has a twelve month low of $101.61 and a twelve month high of $194.88. The company has a market capitalization of $9.32 billion, a P/E ratio of 118.60 and a beta of 1.19.

Masimo (NASDAQ:MASI - Get Free Report) last issued its quarterly earnings results on Tuesday, May 6th. The medical equipment provider reported $1.36 earnings per share for the quarter, topping analysts' consensus estimates of $1.24 by $0.12. The business had revenue of $372.00 million for the quarter, compared to analyst estimates of $367.79 million. Masimo had a return on equity of 14.98% and a net margin of 3.85%. The company's revenue was down 24.5% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.77 earnings per share. On average, analysts forecast that Masimo Co. will post 4.1 EPS for the current year.

Insiders Place Their Bets

In related news, COO Bilal Muhsin sold 10,000 shares of the company's stock in a transaction that occurred on Monday, May 12th. The stock was sold at an average price of $163.28, for a total value of $1,632,800.00. Following the sale, the chief operating officer now owns 24,172 shares in the company, valued at $3,946,804.16. This represents a 29.26% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Craig B. Reynolds sold 2,053 shares of Masimo stock in a transaction on Friday, March 14th. The shares were sold at an average price of $166.13, for a total transaction of $341,064.89. Following the completion of the transaction, the director now directly owns 16,581 shares of the company's stock, valued at $2,754,601.53. The trade was a 11.02% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 42,053 shares of company stock valued at $6,998,565. Insiders own 9.70% of the company's stock.

Masimo Profile

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.